LAUSR

Leishmaniasis is a cutaneous, mucocutaneous, or visceral parasitic disease caused by protozoa of the Leishmania genus. According to the World Health Organization, Leishmaniasis causes approximately 20-40 thousand deaths annually, and Brazil, India, and some countries in Africa are the most affected by this neglected disease. In addition to parasite's ability to evade the host's immune system, the incidence of vectors, the genetics of different hosts, and the large number of deaths are mainly due to failures in conventional treatments that have high toxicity, low effectiveness, and prolonged therapeutic regimens. Thus, the development of new alternative therapeutics with more effective and safer actions has become one of the main challenges for researchers studying leishmaniasis. Among the many research and tested options, metallic nanoparticles, such as gold, silver, zinc oxide, and titanium dioxide, have been shown to be one of the most promising therapeutic tool because they are easily prepared and chemically modified, have a broad spectrum of action, low toxicity, and can generate reactive oxygen species and other immune responses that favor their use against different species of Leishmania. This review explores the progress of the use of metallic nanoparticles as a new tool in the treatment of leishmaniasis, as well as discusses the gaps in knowledge that need to be addressed to consolidate a safe, effective, and definitive therapeutic intervention against these infections.